Metastatic Breast Cancer Clinical Trials

A listing of 66 Metastatic Breast Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Metastatic Breast Cancer

1 - 12 of 66

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 66 active clinical trials seeking participants for Metastatic Breast Cancer research studies. The states with the highest number of trials for Metastatic Breast Cancer participants are Texas, California, Florida and New York.

Featured Trial

Healthy Participants Needed (Colonoscopy + Cancer Screening)

Recruiting

Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.

Conditions:

Healthy

Healthy Volunteers

Healthy Subjects

Healthy Volunteer

Healthy Participants

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Featured Trial

Stroke Clinical Study

Recruiting

A clinical study for people that suffer with Stroke

Conditions:

Stroke

Learn More

Featured Trial

Chronic Kidney Disease (CKD) Clinical Study

Recruiting

A clinical study for people that suffer with Chronic Kidney Disease (CKD)

Conditions:

Chronic Kidney Disease (CKD)

Learn More

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer

NCT06557148

Recruiting

The purpose of this study to compare two types of cancer imaging scans to see which is better at detecting and monitoring metastatic ILC. This study will compare PET/CT (positron emission tomography/computed tomography) scans using the radiotracer fluorine 18 (18F)-fluoroestradiol (FES) with a standard imaging approach for detecting and monitoring ILC, PET/CT scans using the radiotracer 18F-fluorodeoxyglucose (FDG). These scans will be referred to as FES PET/CT scans and FDG PET/CT scans.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/22/2025

Locations: Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Breast Cancer, Lobular Breast Carcinoma, Breast Carcinoma, Metastatic Breast Cancer, Metastatic Lobular Breast Carcinoma, Metastatic Breast Carcinoma

Learn More ›

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

NCT06756932

Recruiting

The purpose of this study is to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/19/2025

Locations: Hoag Memorial Presbyterian, Newport Beach, California +15 locations

Conditions: Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

HER-2 B Cell Peptide Vaccine

NCT06414733

Recruiting

This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors. Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/19/2025

Locations: Indiana University Melvin & Bren Simon Comprehensive Cancer Center, Indianpolis, Indiana

Conditions: Metastatic Breast Cancer, Metastatic Gastrointestinal Carcinoma, HER2-positive Breast Cancer, HER2-positive Gastric Cancer, EGFR Overexpression

Learn More ›

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Recruiting

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/19/2025

Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +62 locations

Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Duke Cancer Center, Durham, North Carolina

James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Scri Oncology Partners, Nashville, Tennessee

The University of Texas Md Anderson Cancer Center, Houston, Texas

Next Dallas, Irving, Texas

Next Oncology, San Antonio, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Southern Highlands Private Hospital, Bowral, New South Wales

Concord Repatriation General Hospital, Concord, New South Wales

Macquarie University, North Ryde, New South Wales

Townsville University Hospital, Douglas, Queensland

Genesiscare St Andrews, Adelaide, South Australia

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Centro de Pesquisas Oncologicas Cepon, Florianopolis, Not set

Liga Norte Riograndene Contra O Cancer, Natal, Not set

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Not set

Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Not set

Instituto Nacional de Cancer, Rio de Janeiro, Not set

Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Not set

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, Not set

Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, Sao Paulo, Not set

Hospital Israelita Albert Einstein, Sao Paulo, Not set

Beijing Cancer Hospital, Beijing, Beijing

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Centre Francois Baclesse, Caen, Not set

Centre Oscar Lambret, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

Institut Curie, Paris, Not set

Centre Eugene Marquis, Rennes, Not set

Institut de Cancerologie de Louest, St Herblain, Not set

Institut Gustave Roussy, Villejuif, Not set

Nagoya University Hospital, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Shizuoka Cancer Center, Suntogun, Shizuoka

Seoul National University Bundang Hospital, BundangGu SeongnamSi, Gyeonggi-do

Korea University Anam Hospital, SeongbukGu, Gyeonggi-do

Gachon University Gil Medical Center, NamdongGu, Incheon Gwang'yeogsi

Samsung Medical Center, GangnamGu, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, SeochoGu, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, SeodaemunGu, Seoul Teugbyeolsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Asan Medical Center, SongpaGu, Seoul Teugbyeolsi

Pulau Pinang Hospital, Georgetown, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Sarawak General Hospital, Kuching, Not set

National Cancer Institute (Institut Kanser Negara), Putrajaya, Not set

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Harbour Cancer and Wellness, Auckland, Not set

Nzcr Christchurch, Christchurch, Not set

Srinagarind Hospital (Khon Kaen University), Muang, Not set

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer

Learn More ›

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

NCT06324357

Recruiting

This study is open to adults aged 18 years and older with different types of HER2+ cancer that has spread and cannot be removed by surgery. People can take part in this study if their tumours show HER2 aberrations and previous treatment was not successful. The purpose of this study is to find a suitable dose of zongertinib that people with different types of HER2+ cancer that has spread can tolerate best when taken together with trastuzumab deruxtecan (T-DXd), with trastuzumab emtansine (T-DM1),... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: The Oncology Institute of Hope and Innovation, Cerritos, California +79 locations

The Oncology Institute of Hope and Innovation, Cerritos, California

Valkyrie Clinical Trials, Los Angeles, California

University of California Irvine, Orange, California

Sharp Memorial Hospital, San Diego, California

Yale University School of Medicine, New Haven, Connecticut

Community Health Network, Indianapolis, Indiana

University of Iowa Hospitals and Clinics, Iowa City, Iowa

Massachusetts General Hospital, Boston, Massachusetts

Dana-Farber Cancer Institute, Boston, Massachusetts

Memorial Sloan-Kettering Cancer Center, New York, New York

Baptist Cancer Center - Memphis, Memphis, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Tennessee Oncology, Pllc, Nashville, Tennessee

The Methodist Hospital Research Institute, Houston, Texas

Virginia Cancer Specialists, PC, Fairfax, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

Brussels - UNIV Saint-Luc, Bruxelles, Not set

Edegem - UNIV UZ Antwerpen, Edegem, Not set

UZ Leuven, Leuven, Not set

UZ Antwerpen, Libramont-Chevigny, Not set

Centre Hospitalier Universitaire de Liège, Liege, Not set

CHU UCL Namur - Site De Sainte-Elisabeth, Namur, Not set

Jilin Province Cancer Hospital, Changchun, Not set

The First Hospital of Jilin University, Changchun, Not set

Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine, Hangzhou, Not set

Harbin Medical University Cancer Hospital, Harbin, Not set

Jiangsu Province Hospital, Nanjing, Not set

Fudan University Shanghai Cancer Center, Shanghai, Not set

Tianjin Cancer Hospital, Tianjin, Not set

Henan Cancer Hospital, Zhengzhou, Not set

INS Bergonie, Bordeaux cedex, Not set

CTR François Baclesse, Caen, Not set

CTR Georges-François Leclerc, Dijon, Not set

CTR Leon Berard, Lyon, Not set

INS Paoli-Calmettes, Marseille Cedex 9, Not set

HOP Tenon, Paris, Not set

CTR Eugène Marquis, Rennes cedex, Not set

Institut de Cancérologie de l'Ouest, Saint Herblain, Not set

Institut de Cancérologie de Strasbourg, Strasbourg, Not set

INS Claudius Regaud IUCT-Oncopole, Toulouse, Not set

Universitätsklinikum Carl Gustav Carus Dresden, Dresden, Not set

Evang. Kliniken Essen-Mitte gGmbh, Essen, Not set

Asklepios Kliniken GmbH & Co. KGaA, Hamburg, Not set

Istituto Di Candiolo, Candiolo (TO), Not set

Az.Osp. Universitaria "Ospedali Riuniti", Foggia, Not set

Istituto Scientifico Romagnolo, Meldola (fc), Not set

IRCCS San Raffaele, Milano, Not set

Istituto Europeo di Oncologia, Milano, Not set

Humanitas Istituto Clinico Catanese S.p.A., Misterbianco (CT), Not set

Istituto Nazionale IRCCS Tumori Fondazione Pascale, Napoli, Not set

Istituto Clinico Humanitas, Rozzano, Not set

Aichi Cancer Center Hospital, Aichi, Nagoya, Not set

Hakuaikai Sagara Hospital, Kagoshima-shi, Not set

Tokai University Hospital, Kanagawa, Isehara, Not set

Kanagawa Cancer Center, Kanagawa, Yokohama, Not set

National Cancer Center Hospital East, Kashiwa-shi, Not set

Kyoto University Hospital, Kyoto, Kyoto, Not set

Osaka International Cancer Institute, Osaka-shi, Not set

Japanese Foundation for Cancer Research, Tokyo, Koto-ku, Not set

CHA Bundang Medical Center, Seongnam-si, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Hospital Teresa Herrera, A Coruña, Not set

Hospital del Mar, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital Clínic de Barcelona, Barcelona, Not set

Hospital Duran i Reynals, L'Hospitalet de Llobregat, Not set

Hospital General Universitario Gregorio Marañón, Madrid, Not set

Clínica Universidad de Navarra - Madrid, Madrid, Not set

Fundación Jiménez Díaz, Madrid, Not set

Hospital Clínico San Carlos, Madrid, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital La Paz, Madrid, Not set

CIO Clara Campal, Madrid, Not set

Hospital Virgen Macarena, Sevilla, Not set

Instituto Valenciano de Oncología, Valencia, Not set

St James's University Hospital, Leeds, Not set

St Bartholomew's Hospital, London, Not set

Nottingham University Hospitals NHS Trust, Nottingham, Not set

Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma

Learn More ›

A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

NCT06110793

Recruiting

The purpose of this study is to test whether the combination of lenvatinib, pembrolizumab, and fulvestrant is a safe and effective treatment that causes few or mild side effects in people with ER+/HER2- metastatic breast cancer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/14/2025

Locations: Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey +6 locations

Conditions: Metastatic Breast Cancer

Learn More ›

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

NCT06428396

Recruiting

The purpose of this study is to assess the efficacy and safety of belzutifan (MK-6482) plus fulvestrant compared to everolimus plus endocrine therapy (ET) (investigator's choice of fulvestrant or exemestane) in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) unresectable metastatic breast cancer. There is no formal hypothesis testing in this study.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: City of Hope - Phoenix ( Site 0006), Goodyear, Arizona +36 locations

City of Hope - Phoenix ( Site 0006), Goodyear, Arizona

Cedars Sinai Medical Center ( Site 0012), Beverly Hills, California

Moores Cancer Center at UC San Diego Health ( Site 0025), La Jolla, California

USC/Norris Comprehensive Cancer Center ( Site 0013), Los Angeles, California

USC Norris Oncology Hematology Newport Beach ( Site 0029), Newport Beach, California

Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0011), Marietta, Georgia

Southeastern Regional Medical Center ( Site 0010), Newnan, Georgia

CHRISTUS Highland ( Site 0005), Shreveport, Louisiana

Renown Regional Medical Center ( Site 0018), Reno, Nevada

MD Anderson ( Site 0015), Houston, Texas

Mays Cancer Center ( Site 0022), San Antonio, Texas

Centro de Investigaciones Metabólicas (CINME)-Oncology ( Site 0504), Caba, Buenos Aires

Hospital Británico de Buenos Aires-Oncology ( Site 0500), Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0502), Mar del Plata, Buenos Aires

Instituto Alexander Fleming-Alexander Fleming ( Site 0505), Ciudad Autónoma de Buenos Aires, Caba

Sanatorio Allende - Cerro-Oncology ( Site 0506), Córdoba, Cordoba

Instituto de Oncología de Rosario ( Site 0501), Rosario, Santa Fe

Jewish General Hospital ( Site 0400), Montreal, Quebec

Centro de Investigación del Maule ( Site 4106), Talca, Maule

Bradfordhill ( Site 4100), Santiago., Region M. De Santiago

FALP ( Site 4102), Santiago, Region M. De Santiago

Pontificia Universidad Catolica de Chile ( Site 4108), Santiago, Region M. De Santiago

IMAT S.A.S ( Site 1205), Monteria, Cordoba

Oncologos Del Occidente ( Site 1200), Pereira, Risaralda

Fundacion Valle del Lili ( Site 1204), Cali, Valle Del Cauca

Seoul National University Hospital ( Site 3100), Seoul, Not set

Samsung Medical Center ( Site 3101), Seoul, Not set

National Cheng Kung University Hospital ( Site 3300), Tainan, Not set

National Taiwan University Hospital ( Site 3301), Taipei, Not set

National Taiwan University Cancer Center ( Site 3302), Taipei, Not set

Faculty of Medicine - Khon Kaen University ( Site 3502), Muang, Khon Kaen

Faculty of Medicine Siriraj Hospital ( Site 3500), Bangkoknoi, Krung Thep Maha Nakhon

Songklanagarind Hospital ( Site 3501), Hat Yai, Songkhla

The Royal Cornwall Hospital ( Site 1904), Truro, England

St Bartholomews Hospital ( Site 1900), London, London, City Of

The Christie Hospital NHS Foundation Trust ( Site 1902), Withington, Manchester

Ipswich Hospital ( Site 1911), Ipswich, Suffolk

Conditions: Metastatic Breast Cancer

Learn More ›

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

NCT06827236

Recruiting

This is a Phase I/II, multi-site, open-label, two-part study designed to evaluate the efficacy, safety, optimized dose and contribution of components of BNT323 in combination with BNT327 in participants with hormone receptor-positive (HR+) or hormone receptor-negative (HR-), Human epidermal growth factor receptor (HER)2-positive, HER2-low (immunohistochemistry \[IHC\] 1+ or IHC 2+/in situ hybridization -), HER2-ultralow (IHC 0, with membrane staining) or HER2-null breast cancer (BC), or triple-n... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/12/2025

Locations: Hematology - Oncology Associates of the Treasure Coast, Port Saint Lucie, Florida +6 locations

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Unresectable Breast Carcinoma

Learn More ›

CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer

NCT05029999

Recruiting

This research study is being done to find out if the immunotherapy drugs called CDX-301 and CDX-1140 in combination with the standard chemotherapy treatment pegylated liposomal doxorubicin (PLD, Doxil) are safe and effective at controlling the cancer in patients with metastatic triple Human Epidermal Growth Factor Receptor 2 (HER2) negative breast cancer, and to determine a safe dose and treatment schedule of the three drugs. This research study will also test how your immune system responds to... Read More

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

08/11/2025

Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +6 locations

Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer

Learn More ›

Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857

Recruiting

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: Research Facility, Phoenix, Arizona +22 locations

Conditions: Metastatic Breast Cancer, HER2-negative Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer

Learn More ›

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer

NCT03424005

Recruiting

This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, four cohorts will be enrolled in parallel in this study: Cohort 1 will consist of Programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/07/2025

Locations: City of Hope, Duarte, California +41 locations

City of Hope, Duarte, California

University of California San Diego Medical Center, La Jolla, California

Stanford Cancer Institute, Stanford, California

Rocky Mountain Cancer Center - Longmont, Longmont, Colorado

H. Lee Moffitt Cancer Center and Research Inst., Tampa, Florida

Hackensack Univ Medical Center, Hackensack, New Jersey

Regional Cancer Care Associates, LLC, Howell, New Jersey

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

NYU Langone Medical Center, New York, New York

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

The West Clinic, Germantown, Tennessee

Vanderbilt University Medical Center, Nashville, Tennessee

Texas Oncology-Plano East, Plano, Texas

Peter MacCallum Cancer Centre-East Melbourne, Melbourne, Victoria

Fiona Stanley Hospital - Medical Oncology, Murdoch, Western Australia

Centre Léon Bérard, Lyon, Not set

Institut régional du Cancer Montpellier, Montpellier, Not set

Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, Not set

Gustave Roussy, Villejuif, Not set

Universitätsklinikum Erlangen, Erlangen, Not set

Universitätsklinikum Essen, Essen, Not set

Rambam Medical Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Hadassah University Medical Center, Jerusalem, Not set

Rabin MC, Petach Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Tel-Aviv Sourasky Medical Center, Tel Aviv, Not set

Assuta Medical Centers, Tel Aviv, Not set

National Cancer Center Clinical Trials Center / Center for Breast Cancer, Goyang-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital, Seoul, Not set

University of Ulsan College of Medicine - Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Hospital del Mar, Barcelona, Not set

Vall d?Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, Not set

Hospital Universitario Ramon y Cajal, Madrid, Not set

Centro Integral Oncológico Clara Campal Ensayos Clínicos START, Madrid, Not set

Hospital Universitario Virgen Macarena, Sevilla, Not set

National Cheng Kung University Hospital, Tainan City, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Barts Health NHS Trust - St Bartholomew's Hospital, London, Not set

Conditions: Metastatic Breast Cancer

Learn More ›

A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors

NCT06157892

Recruiting

This clinical trial is studying solid tumor cancers. A solid tumor is one that starts in part of your body like your lungs or liver instead of your blood. Once they've grown bigger in one spot or spread to other parts of the body, they're harder to treat. This is called advanced or metastatic cancer. Participants in this study must have breast cancer or gastric cancer. Participants must have tumors that have HER2 on them. This allows the cancer to grow more quickly or spread faster. There are f... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/06/2025

Locations: Banner-University Medical Center Tucson Campus, Tucson, Arizona +122 locations

Banner-University Medical Center Tucson Campus, Tucson, Arizona

Banner-University Medical Center Tucson, Tucson, Arizona

The University of Arizona Cancer Center-North Campus Pharmacy, Attn: Kelly Myrdal, Tucson, Arizona

University of Arizona Cancer Center - North Campus, Tucson, Arizona

The University of Arizona Cancer Center-Main, Tucson, Arizona

UC Irvine Medical Center, Orange, California

University of California, San Francisco | HDFCCC - Hematopoietic Malignancies, San Francisco, California

UCLA Department of Medicine - Hematology & Oncology, Santa Monica, California

Colorado West Healthcare System, dba Community Hospital, Grand Junction, Colorado

Colorado West Healthcare, dba Grand Valley Oncology, Grand Junction, Colorado

Danbury Hospital, Danbury, Connecticut

The Whittingham Cancer Center / Norwalk Hospital, Norwalk, Connecticut

Georgetown University Medical Center, Washington, District of Columbia

MedStar Georgetown University Hospital, Washington, District of Columbia

Moffitt Cancer Center - International Plaza, Tampa, Florida

H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida

Moffitt Cancer Center - McKinley Campus, Tampa, Florida

Moffitt McKinley Hospital, Tampa, Florida

Moffitt Cancer Center at Wesley Chapel, Wesley Chapel, Florida

Georgia Cancer Specialists - Athens, Athens, Georgia

Georgia Cancer Specialists - Annex, Atlanta, Georgia

Atlanta Cancer Care - Atlanta, Atlanta, Georgia

Georgia Cancer Specialists-Northside, Atlanta, Georgia

Northside Hospital, Inc.- Central Research Department, Atlanta, Georgia

Northside Hospital, Atlanta, Georgia

Georgia Cancer Specialists - Blairsville, Blairsville, Georgia

Georgia Cancer Specialists - Canton, Canton, Georgia

Atlanta Cancer Care - Cumming, Cumming, Georgia

Georgia Cancer Specialists - Cumming, Cumming, Georgia

Georgia Cancer Specialists - Decatur, Decatur, Georgia

Suburban Hematology-Oncology Associates - Duluth, Duluth, Georgia

Suburban Hematology-Oncology Associates- Lawrenceville, Lawrenceville, Georgia

Georgia Cancer Specialists - Macon, Macon, Georgia

Georgia Cancer Specialists - Marietta, Marietta, Georgia

Memorial Hospital, Shiloh, Illinois

Siteman Cancer Center - Shiloh, Shiloh, Illinois

Massachusetts General Hospital., Boston, Massachusetts

Brigham and Women's Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Dana Farber Cancer Institute- Chestnut Hill, Newton, Massachusetts

Siteman Cancer Center - West County, Creve Coeur, Missouri

Siteman Cancer Center - North County, Florissant, Missouri

Saint Luke's Cancer Institute LLC, Kansas City, Missouri

Saint Luke's Hospital Investigational Pharmacy, Kansas City, Missouri

St Lukes Hospital, Kansas City, Missouri

Barnes-Jewish Hospital, Saint Louis, Missouri

Washington University in St Louis., Saint Louis, Missouri

Washington University School of Medicine - Siteman Cancer Center, Saint Louis, Missouri

Siteman Cancer Center - South County, Saint Louis, Missouri

Siteman Cancer Center - St Peters, Saint Peters, Missouri

Renown Regional Medical Center, Reno, Nevada

San Juan Oncology Associates, Farmington, New Mexico

Memorial Sloan Kettering Cancer Center - Main Hospital, New York, New York

Zangmeister Cancer Center, Columbus, Ohio

Saint Francis Hospital / Bon Secours - South Carolina, Greenville, South Carolina

Sarah Cannon Research Institute - Pharmacy, Nashville, Tennessee

SCRI Oncology Partners, Nashville, Tennessee

Tennessee Oncology-Nashville/Sarah Cannon Research Institute, Nashville, Tennessee

Parkland Health and Hospital System, Dallas, Texas

University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas, Texas

University of Texas Southwestern Medical Center-Simmons Cancer Center Pharmacy, Dallas, Texas

University of Texas Southwestern Medical Center Simmons Cancer Center - Redbird, Dallas, Texas

University of Texas Southwestern Medical Center Clinical Lab-Zale Lipshy University Hospital, Dallas, Texas

University of Texas Southwestern Medical Center-William P. Clements Jr. University Hospital, Dallas, Texas

University of Texas Southwestern Medical Center, Dallas, Texas

University of Texas Southwestern Simmons Cancer Center - Fort Worth, Fort Worth, Texas

University of Texas Southwestern Medical Center Simmons Cancer Center - Richardson/Plano, Richardson, Texas

Harborview Medical Center, Seattle, Washington

Fred Hutchinson Cancer Center / Seattle Cancer Care Alliance / University of Washington, Seattle, Washington

University of Washington Medical Center, Seattle, Washington

University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison, Wisconsin

Carbone Cancer Center / University of Wisconsin, Madison, Wisconsin

Peninsula & South Eastern Hematology and Oncology Group (PASO), Frankston, Victoria

Slade Pharmacy Frankston, Frankston, Victoria

Slade Health, Mount Waverley, Victoria

Peninsula & South Eastern Hematology and Oncology Group (PASO), Frankston, Not set

BC Cancer Kelowna., Kelowna, British Columbia

Ottawa Hospital Cancer Centre, Ottawa, Ontario

Sunnybrook Health Sciences Centre, Toronto, Ontario

University Health Network, Princess Margaret Hospital, Toronto, Ontario

Universitatsklinikum Essen, Essen, Not set

Universitatsklinikum Heidelberg, Heidelberg, Not set

Klinikums rechts der Isar der TU München, Muenchen, Not set

A.O.U. Federico II, Napoli, Campania

Azienda Ospedaliera Universitaria (AOU) Federico II, Napoli, Campania

Istituto Nazionale Tumori IRCCS Fondazione G. Pascale., Napoli, Campania

Istituto Europeo di Oncologia, Milano, Lombardia

Niguarda Ca' Granda Hospital, Milano, Lombardia

Humanitas Istituto Clinico Catanese, Misterbianco (CT), Sicilia

Azienda Ospedaliera Universitaria Integrata di Verona., Verona, Veneto

A.O.U. Federico II- U.O.C. Diagnostica per lmmagini e Radioterapia, Napoli, Not set

Dong-A University Hospital, Busan, Other

National Cancer Center, Goyang-si, Other

Chungbuk National University Hospital, Cheongju-si, Not set

Gachon University Gil Medical Center, Incheon, Not set

Seoul National University Bundang Hospital, Seongnam-si, Not set

Korea University Anam Hospital, Seoul, Not set

Samsung Medical Center, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

St. Vincent's Hospital, The Catholic University of Korea, Suwon-si, Not set

Quirén Salud Barcelona, Barcelona, Not set

Hospital Universitari Vall d´Hebron, Barcelona, Not set

CETIR Grup Medic, Barcelona, Not set

Hospital Universitario de Basurto, Bilbao, Not set

Grupo Hospitalario QuironSalud, Erandio Bizkaia, Not set

L'Institut Catala d'Oncologia., L'Hospitalet de Llobregat, Not set

Farmacia-Ensayos. Planta S - Hospital Universitario HM Sanchinarro-CIOCC-START Madrid, Madrid, Not set

START Madrid-CIOCC_Hospital HM Sanchinarro, Madrid, Not set

Ecg Medica Sl, Valencia, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

National Taiwan University Cancer Center, Taipei, Not set

The Royal Marsden Hospital, Sutton, Surrey

St Bartholomew's Hospital, London, Not set

The Royal Marsden Hospital, London, Not set

The Royal Marsden NHS Foundation Trust (RM), London, Not set

The Christie NHS Foundation Trust, Manchester, Not set

The Royal Marsden NHS Foundation Trust, Sutton, Not set

Conditions: Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer

Learn More ›

1 - 12 of 66